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Abstract Advanced stages of Parkinson’s disease (advPD)
still impose a challenge in terms of classification and related
stage-adapted treatment recommendations. Previous con-
cepts that define advPD by certain milestones of motor
disability apparently fall short in addressing the increasingly
recognized complexity of motor and non-motor symptoms
and do not allow to account for the clinical heterogeneity
that require more personalized approaches. Therefore, deep
phenotyping approaches are required to characterize the
broad-scaled, continuous and multidimensional spectrum of
disease-related motor and non-motor symptoms and their
progression under real-life conditions. This will also facili-
tate the reasoning for clinical care and therapeutic decisions,
as neurologists currently have to refer to clinical trials that
provide guidance on a group level; however, this does not
always account for the individual needs of patients. Here, we
provide an overview on different classifications for advPD
that translate into critical phenotypic patterns requiring the
differential therapeutic adjustments. New concepts refer to
precision medicine approaches also in PD and first studies
on genetic stratification for therapeutic outcomes provide a
potential for more objective treatment recommendations.
We define novel treatment targets that align with this con-
cept and make use of emerging device-based assessments of
real-life information on PD symptoms. As these approaches
require empowerment of patients and integration into treat-
ment decisions, we present communication strategies and
decision support based on new technologies to adjust treat-
ment of advPD according to patient demands and safety.
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What is advanced Parkinson’s disease?
The traditional classification and disease progression of
Parkinson’s disease (PD) orient on disease milestones that
can be most obviously followed along motor domains. In
this sense, the topography and severity of segmental motor
symptoms, followed by more bilateral segmental involve-
ment, finally appearance of gait disturbance, postural
impairment and bedridden immobile states provide well
defined but also in some way broadly scaled categories of
disease stages. Although this and similar classifications are
valuable to approximate and describe the motor severity
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over time, the classifications fall short to comprehensively
describe and characterize the full, continuous and multi-
dimensional spectrum of disease-related motor and non-
motor symptoms. In recent years, diverse non-motor
domains, quality of life, psychosocial burden and stigma
have received major attention as determinants of PD dis-
ease course and outcome parameters of clinical trials
(Deuschl et al. 2006; Schuepbach et al. 2013). Diversity in
neurodegeneration patterns and involvement of several
neurotransmitters and their contribution to motor and non-
motor symptom parallel the phenotypic variability
(Sauerbier et al. 2016a; Titova et al. 2016).
Characterizing PD patients on such broad scales is essen-
tial, since the phenotype of individual patients varies sub-
stantially. This diversity leads to ultimate differences in
patients’ therapeutic requirements, and will very differentially
affect patients’ subjective well-being, self-perceived disease-
related impairments, and health-related quality of life.
Thus, the following questions remain: when one would
talk from advanced PD (advPD)? Would it be the presence
of a particularly severe symptom? Would it be the com-
bination of different symptoms as red flags? Would it be
more rapid progression? What is the respective threshold
for considering treatment escalation? And, who would
finally decide that an advPD stage was reached? A general
practitioner, an expert neurologist? Or should the patient’s
self-perception even prompt severity categorization?
Indeed, there is no uniquely accepted operationalization to
this end and, thus, the additional efforts are justified to
address this yet unmet need (Antonini et al. 2015; Luquin
et al. 2017). An approximation towards a unique definition of
advPD was strongly proclaimed recently—in particular to
ensure referral of the right patient to an adequate therapeutic
regimen at the right time. This should help to refer patients to
specialized centers for introduction of advanced therapies
like neurostimulation or continuous dopaminergic pump
therapies, following recommendations from randomized
controlled trials (Odin et al. 2015; Olanow et al. 2014;
Deuschl et al. 2006). Owing to this perspective, classifying a
PD patient as ‘‘advanced’’ would sensitize patients, care-
givers, and non-specialized general practitioners, as well as
specialized expert neurologists to prompt therapy referral at
the right time—ultimately right before the patient would
suffer for years from an unaddressed therapeutic gap by
missing adequate and effective therapy, which would put the
patient at risk for irreversible and handicapping sequelae
(Odin et al. 2015). This needs to include both motor and non-
motor domains and implies a more holistic view of PD
(Sauerbier et al. 2016a). Further hallmarks of the late disease
stage clearly outweigh a focus on motor and non-motor
complication along disease progression. This mainly incor-
porates cognitive incompetence, uncontrolled psychiatric
issues like psychosis, or resistant axial motor symptoms like
imbalance or gait impairment that finally would imply loss of
self-dependence and increasing dependence on care (Kru¨ger
et al. 2015; Weiss et al. 2013).
Another critical and unaddressed issue when guiding
therapy along evidence-based medicine is the potential bias
from classical clinical trials, since study cohorts that are
generally based on strict inclusion and exclusion criteria and,
therefore, cannot sufficiently represent the overall PD popu-
lation as a whole. In other words, such trials generally under-
represent ‘common’ PD patients with multiple co-morbidi-
ties. However, these patients constitute the most relevant and
demanding treatment group in routine daily practice (Spren-
ger et al. 2014). Therefore, evidence-based medicine deduced
from classical trials may fail to translate into daily life clinical
practice in a relevant proportion of patients—notwithstanding
the important merits of such high-quality trials.
Current treatment of PD is characterized by polyphar-
macy and, therefore, implies potential complications
through interactions between different medications.
Moreover, different pharmacokinetic aspects have to be
considered. First of all, gastric emptying in patients with
PD is slowed in advanced stages of the disease with a
relevant influence on absorption (Nyholm 2006). Regard-
ing the biotransformation, most anti-parkinson drugs are
metabolized hepatically and only amantadine is mainly
excreted unchanged via the kidney (Hiemke et al. 2011).
Practical aspects of therapy of advPD focus on treatment
optimization under changing pharmacokinetic and phar-
macodynamic conditions (Mu¨ller 2012).
Regarding the risk of side effects by a drug–drug
interaction, it must be considered that PD predominantly is
a disease of the elderly (Wright Willis et al. 2010).
Therefore, most of these patients suffer from different
diseases, and in the consequence often enough are treated
with a whole range of different medications (Csoti et al.
2016). Polypharmacy in the elderly is commonly per-
formed with the number of drugs increasing in parallel with
patient’s age (Cascorbi 2012). Besides bromocriptine as
CYP3A4 inhibitor, anti-parkinson medication itself has no
properties of pharmacokinetic induction or inhibition
(Hiemke et al. 2011). Although anti-parkinsonian medica-
tion generally seems to play no relevant role in drug–drug
interaction described on neurology wards (Namazi et al.
2014), drug–drug interaction studies in PD give sugges-
tions for treatment in patients with comorbidities like
arterial hypertension (Bitner et al. 2015) or diabetes mel-
litus and other internal medicine diseases (Csoti et al.
2016). These complex interactions in multi-morbid advPD
patients justify and add value to observational studies
related to novel treatment options that may contribute real-
life information on the usefulness of new therapeutic
options (Pa˚lhagen et al. 2016). Here, registers and collec-
tion of real-life data are encouraged to obtain larger and
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unselected data pools and to complement evidence-based
medicine.
Together, patient demands and neurologist reasoning on
clinical care and therapeutic decision are highly complex
and multidimensional. Owing to the complexity of clinical
decisions, classical clinical trials that are guiding elements
of evidence-based medicine can justify clinical decision
making on a group level according to specifically defined
criteria, but may fall short for an individual patient given the
complexity and interindividual variability of phenotype and
patient demands. This consideration prompted the so-called
‘precision medicine’ concept (Robinson 2012), i.e., it is
expected that an in-depth precise phenotyping would finally
guide the physician towards the best individual care for an
individual patient and his/her personal needs and require-
ments. Integration of both objective and subjective surro-
gates—according to the so-called ‘patient-and-physician
partnering perspective’ as part of the Parkinson Net in the
Netherlands (Gray et al. 2016)—might finally imply a dif-
ferent operationalization of the term ‘‘advPD’’. In this sense,
advPD would not adhere too tightly on disease milestones
and progression, but might rather reflect distinct phenotype
scenarios across the very broad-scaled and multidimensional
PD phenotype (including motor, non-motor, quality of life,
psychosocial, contextual aspects). If so, advPD would rather
point to critical phenotypic presentations needing therapeu-
tic adjustment (as opposed to a pure ‘disease stage
approach’). In such an ideal and highly differentiated
framework, deep phenotyping would prompt and differen-
tiate clinical decisions along the multimodal features to
guide therapy towards its utmost precision and safety.
Strategies to define diseases stages
As already stated in the introductory part, there are many
possibilities to classify or subtype PD: age of onset, clinical
phenotypes (motor and non-motor), disease severity or
neuropathological alterations. We here present the current
scientific knowledge of frequently used classifications and
thereby want to provide the basis for subsequent stratifi-
cation of patients, that is needed to identify the optimal
treatment for the individual patient. We acknowledge that a
classification or staging of PD as a heterogeneous neu-
rodegenerative disease is to some extent artificial, but still
consider it important, especially in view of the emerging
highly specific causative treatment concepts.
Disease onset of PD: juvenile, early and typical
forms
A frequently applied classification of PD depends on the
time point of disease onset. Juvenile PD develops until an
age of 20 years, early onset PD until 40 years (some
authors enlarge the time frame until age 45). Thereafter,
development of disease is regarded as a normal onset. In
the case of juvenile or early onset PD before the age of
35 years, a further genetic analysis, even in the absence of
a positive family history, as typically related to an auto-
somal recessive inheritance with unaffected parents, is
worthwhile (Sheerin et al. 2014). Early onset patients
typically present with a more benign disease course and are
less frequently subject to cognitive impairments; however,
motor fluctuations are typically observed and can justify
interventional treatment options within the advPD concept
(Hassan et al. 2015) Generally, these forms of PD are
typically rare and as a chronic-progressive neurodegener-
ative disease, most patients are diagnosed at a rather
advanced age. Thus, at the age of 65, the incidence
amounts to approximately 50 in 100,000, at age 75–150 in
100,000, and at age 85–400 in 100,000 (de Lau et al. 2006;
Pringsheim et al. 2014). In an elaborate approach to
approximate the prevalence of prodromal PD—which
might be present already about 10 years before clinical
diagnosis—Berg et al. calculated a prodromal prevalence
of 0.5% at age 55, 1.5% at age 65, and 4% at age 75 (Berg
et al. 2015). This means that at the age of 75 years about
1% of the population will be diagnosed with PD, but an
additional 4% will already have prodromal PD and might
develop the classical motor symptoms within the next
10 years. With these numbers, the strong impact of PD for
our aging society becomes obvious.
Overall clinical disease classification and motor
scales: HY stage and UPDRS scale
In an early study of PD patients between 1949 and 1964,
Margaret M. Hoehn and Melvin D. Yahr classified patients
based on their degree of disability into five categories, the
widely used HY stages I–V. Among all patients classified
accordingly, the proportion of those who were severely
disabled or dead within 5 years of disease onset was about
25 percent. After follow-up for 5–9 years, this percentage
increased to 67, and to 80% after 10–14 years. Only a
small group of patients showed a slower disease progres-
sion and maintained balance and postural stability for more
than 10 years, some even lacking severe disability more
than 20 years later (Hoehn and Yahr 1967). In a more
recent study of 142 PD patients who had been long-term
followed from 2000 to 2012, about 77% had an advanced
outcome at 10 years after diagnosis which was mostly due
to dementia or postural instability. Most causes of death
were not directly related to PD but consisted in pneumonia,
cancer, cardiac disease and other reasons (Williams-Gray
et al. 2013). It is important to note that the transition from
HY stage II to III marks a milestone in PD, because disease
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impairment with gait and balance difficulties results in
overt disease disability and restricts gait-dependent
activities.
While strengths of the HY scale are its wide utilization
and acceptance as well as a correlation to standardized
scales for motor impairment, disability, and some aspects
of quality of life, it has also weaknesses. Of these, the
scale’s mixing of impairment and disability and the non-
linearity of the scale are most important (Goetz et al.
2004). Therefore, more differentiated scales with focus on
motor impairment including the cardinal symptoms of PD
(hypo-/bradykinesia, rigidity, rest tremor, postural insta-
bility) have been developed and can additionally be
applied. Here, the Unified Parkinson Disease Rating Scale
(UPDRS) or a modified form as proposed by the MDS
(MDS-UPDRS) is available (Movement Disorder Society
Task Force on Rating Scales for Parkinson’s Disease.
2003; Goetz et al. 2004, 2008). Basically, the scale con-
tains four domains consisting of cognition and mood (part
I: non-motor experiences of daily living), activities of daily
living (part II: motor experiences of daily living), motor
examination (part III), and motor complications (part IV).
It has a high validity for rating in PD as was shown after an
elaborate clinimetric test of the scale (Goetz et al. 2008).
Based on the MDS-UPDRS scores, cutoff points to sub-
classify PD patients were proposed recently. Here, cutoffs
in each of the four parts of the scale were defined for mild,
moderate or severe stages (cutoff points between
mild/moderate and moderate/severe levels as follows: Part
1: 10/11 and 21/22; Part 2: 12/13 and 29/30; Part 3: 32/33
and 58/59; and Part 4: 4/5 and 12/13). This can help to
better stratify disease severity of PD, identify clinical red
flags for advPD and assign treatment strategies with respect
to overall disease progression and with a focus on motor
symptoms (Martinez-Martin et al. 2015).
Non-motor symptoms and PD subtypes
Parkinson’s disease (PD) has traditionally been considered
a motor system disorder, but it is now widely regarded as
complex disorder with distinct clinical features that also
include neuropsychiatric and non-motor manifestations
(Chaudhuri and Sauerbier 2016). The most relevant non-
motor features comprise cognitive dysfunction and
dementia, psychosis and hallucinations, mood disorders
including depression, anxiety, and apathy/abulia, sleep
disturbances, fatigue, autonomic dysfunction, olfactory
dysfunction, gastrointestinal dysfunction, pain and sensory
disturbances as well as dermatologic findings (seborrhea).
Although these symptoms are in part included in the MDS-
UPDRS scale, more specific scales exist which exclusively
evaluate non-motor function such as the patient self-ques-
tionnaire NMS-Quest (Chaudhuri et al. 2006) or the
physician-assisted NMS Scale (Chaudhuri et al. 2007).
These scales capture the non-motor burden of disease and
enable a more holistic view on PD, since non-motor
symptoms were shown to strongly influence overall
severity of disease in PD patients (Chaudhuri et al.
2013, 2015). Moreover, recent classifications of advPD are
clearly referring to non-motor symptoms, e.g., symp-
tomatic dysautonomia (including orthostatic symptomatic
hypotension), excessive daytime sleepiness, hallucinations
and cognitive impairment (Luquin et al., 2017).
While an effort to classify PD according to motor
symptoms into different predominant phenotypes such as
tremor-dominant and non-tremor-dominant (postural
instability gait disorder/akinetic-rigid) subtypes has already
been undertaken, such a classification has recently moved
into focus also for non-motor phenotypes. Here, the fol-
lowing non-motor subtypes are distinguished: cognitive,
neuropsychiatric (apathy, depression/anxiety), sleep (REM
sleep behavior disorder), (central) pain, fatigue, autonomic
(gastrointestinal tract dysfunction, genital-urinary disor-
ders, symptomatic hypotension), and ‘‘Park weight’’
(combined with olfactory dysfunction and dyskinesia)
subtype (Marras and Chaudhuri 2016; Sauerbier et al.
2016b). Interestingly, the non-motor symptom patterns
reflect phenotypes which can be characterized by dominant
involvement of either neocortical, olfactory/limbic or brain
stem areas and thus demonstrate the strong link to the
underlying neuropathological and biochemical (e.g.,
cholinergic, serotonergic, opioidergic, adrenergic) distur-
bances (Marras and Chaudhuri 2016).
Of course, the motor and non-motor symptoms often
overlap to some extent and clinically defined PD subtypes
are unlikely to be distinct non-overlapping entities. Much
more likely, they represent typical phenotypes within a
multidimensional spectrum resulting from variable contri-
butions of several simultaneous pathological processes. In
this context, a frequent association of axial motor symptoms
(i.e., gait disturbances and falls) with cognitive impairments
has been observed that shows the implication of overlapping
functional brain circuits (Amboni et al. 2013; Hausdorff
et al. 2006). This co-occurrence implicates different neu-
ronal structures in the brainstem, cerebellum and cortex and,
therefore, translates into the pathophysiological concept
presented in the following section.
Neuropathological staging
With the help of a precise description of motor and non-
motor phenotypes, a correlation with neuroanatomical
structures and subsequent neuropathological alterations
becomes feasible. In general, idiopathic PD is regarded as a
slowly progressive disease spreading within the nervous
system, which explains that first symptoms are often very
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difficult to pinpoint within an individual patient. Through
very detailed neuropathological analyses of post-mortem
material of PD patients, Braak et al. (2003) and Beach et al.
(2009) described distinct pathways of neuronal degenera-
tion, Lewy body pathology and spreading of disease in the
CNS (Braak et al. 2003; Beach et al. 2009). Braak sug-
gested that the disease process including synucleinopathy
with Lewy body deposition may start in non-dopaminergic
structures in the periphery and then spread in an ascending
way to the olfactory bulb and lower brainstem which could
explain early autonomic disturbances and hyposmia (Braak
stages I/II). Then, brainstem synucleinopathy was found to
migrate rostrally to the substantia nigra pars compacta and
other neuronal clusters of the midbrain and basal forebrain
and classic motor symptoms appear (Stages III/IV). Ulti-
mately, the telencephalic cortex of the temporal and frontal
lobes was shown to be involved (Stages V/VI) (Braak et al.
2003). According to this concept, advPD correlates with
the implication of neocortical structures implying cognitive
impairment. Interestingly and in accordance with the con-
cept of a pathophysiological process affecting dopaminer-
gic and non-dopaminergic structures, patients with a faster
disease progression towards advPD present with earlier
cognitive impairment and postural instability (Van Der
Heeden et al. 2016).
Recently, the validity and predictive utility of Braak
staging have been questioned because the extent of synu-
cleinopathy does not correlate with clinical disease severity
and may also be present in healthy individuals (Parkkinen
et al. 2005). Furthermore, the very common asymmetry of
clinical symptoms is not reflected in disease pathology
(Riederer and Sian-Hu¨lsmann 2012), not to mention pre-
dominantly cognitive disease courses such as Lewy body
dementia, which very early on manifests with cortical
involvement (Halliday et al. 2011; Jellinger 2012). Thus,
novel aetiopathogenic hypotheses of PD emerged, among
them the so-called ‘‘threshold theory’’. It suggests that the
functional threshold is lower for the emergence of early
peripheral and autonomous symptoms before the appear-
ance of the classical motor symptoms of PD because the
functional reserve of the midbrain dopamine and integrated
basal ganglia motor systems to control movement is much
larger than, e.g., for the enteric nervous system (Engelen-
der and Isacson 2017). Through further ongoing analyses, it
will be shown which concept is more robust or if these two
should be harmonized to some extent.
Challenges to classify disease stages at the boundary
of advPD and atypical parkinsonism
During disease progression and based on the predominant
motor and non-motor features associated with advPD, the
separation from atypical parkinsonism (AP) may be
difficult and overlap syndromes like ‘minimal change’
multiple system atrophy (MSA) or progressive supranu-
clear palsy with predominant parkinsonism (PSP-P) have
been described (Petrovic et al. 2012; Respondek and
Ho¨glinger 2016). AP includes a heterogeneous bunch of
syndromes, all characterized by clinically manifest
parkinsonism in combination with other clinical features
and a poor therapeutic response to dopaminergic medica-
tion. Only post-mortem analyses can clearly differentiate
from advPD, as their neuropathology is characteristically
different: in MSA, alpha-synuclein accumulation is found
and defines an alpha-syncleinopathy as PD, but mainly in
glial cells as cytoplasmic inclusions (coiled bodies). In
contrast, PSP and corticobasal degeneration (CBD) are
referred to as tauopathies due to characteristic intraneu-
ronal tau aggregation and some TDP-43 proteinopathies
might also develop clinical parkinsonism (Dickson 2012;
Siuda et al. 2014; Stamelou et al. 2013).
In all parkinsonian syndromes, correct diagnostic clas-
sification is essential for the definition of treatment options
and the accuracy of any prognosis. However, even in
experienced centers, the diagnosis of PD and its diagnostic
differentiation from AP have poor reliability and are often
incorrect, if exclusively based on clinical criteria. In a
number of clinical studies, there is an error rate of at least
10–30% in such cases. Diagnostic accuracy can improve by
consequent use of standardized diagnostic instruments such
as the Queens-Square-Brain-Bank (QSBB)-criteria,
including its supportive signs. QSBB-criteria include
mainly motor symptoms and, therefore, non-motor symp-
toms are under-represented in these criteria. However,
there is still a remarkable difference in the diagnostic
accuracy between experts and non-experts, even if such
standardized criteria are used, and also among experts a
notable percentage of misdiagnosis has been observed in
longitudinal observations (Hughes et al. 1992; Postuma
et al. 2015; Rizzo et al. 2016).
Thus, differentiation of advPD from AP still remains a
diagnostic challenge, especially for slowly progressive
forms of AP that may present substantial overlap with
advanced stages of PD, e.g., in terms of falls, dysphagia
and cognitive impairment (Luquin et al. 2017). In these
rare forms, even dyskinesia can be observed in patients
with MSA that goes beyond phasic dystonia. These can
present as choreatiform and generalized dopamine-induced
dyskinesia and, therefore, complicate the proper diagnosis
of AP (Petrovic et al. 2012). The differentiation between
advPD and AP is critical, as advPD typically defines the
threshold to implement intensified, typically interventional
therapies like pump-systems or DBS. However, patients
with AP have no sustained response to dopaminergic or
neuromodulation treatments and, therefore, the peri-inter-
ventional risk is not justified. This was recently
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underscored in series of neuropathologically confirmed
cases with benign, slowly progressive MSA, who under-
went STN-DBS. Only a subset of these patients showed a
short-term benefit from DBS that was rapidly counteracted
by severely disabling symptoms related to MSA (Meissner
et al. 2016).
In this context, technical tests might further improve the
quality of differential diagnosis. Autonomous tests, such as
tests for cardiovascular, urinary, thermoregulatory or gas-
trointestinal dysfunction can be helpful for the diagnostic
differentiation PD versus AP. Due to a marked overlap, the
combination of several tests such as urodynamic investi-
gation, tests for orthostatic dysregulation, RR-intervals and
sympathetic skin response can contribute to support the
correct diagnosis.
In MSA, olfactory dysfunction is also found in a number
of studies, but has led to controversial results with respect
to its frequency and severity. Yet, in terms of specificity, in
PSP and CBD as well as in vascular parkinsonism the
olfactory function seems to be far less compromised and
may serve for differential diagnosis towards PD but the
result of smell tests can be biased by the fact that slight to
moderate olfactory loss is also found in 20–50% of elderly
healthy subjects (Haehner et al. 2014; Takeda et al. 2014).
Finally, imaging is probably the most frequently used
ancillary examination to differentiate PD from AP. Besides
structural imaging to visualize typical signs for MSA-p
(e.g., pontine and putaminal atrophy, hyperintense putam-
inal rim, hyperintense middle cerebellar peduncle or the
hot-cross bun sign), PSP (midbrain atrophy and an enlarged
third ventricle) and CBD (asymmetric cortical atrophy),
functional brain imaging has been applied. Single photon
emission tomography (SPECT) with various ligands can
help to distinguish PD from AP, e.g., IBZM-SPECT is still
sometimes used for the differentiation PD vs. MSA-p but
has not fulfilled preliminary expectations since clinical
practice has shown that the results are not sufficiently
reliable. However, cardiac MIGB-SPECT has been proven
as a more reliable tool for the identification of AP in early
stages of parkinsonism (Chun et al. 2009).
In summary, there is yet no test available, which has
sufficient sensitivity/specificity for the accurate clinical
diagnostic separation of advPD vs. AP, when it is used
exclusively as an isolated procedure. However, the diag-
nostic accuracy can be improved by the combination of the
above-mentioned ancillary methods in addition to the
physical examination. The exact diagnostic classification is
important for the individual prognosis and patient’s coun-
seling towards interventional therapies, even if the diag-
nosis of AP has limited therapeutic consequences, since
treatment is restricted to symptomatic procedures which
are identical in different forms of AP conditions (Garcia-
Ruiz et al. 2014; Reichmann et al. 2016).
Future deep phenotyping approaches in longitudinal
cohorts may help to further differentiate between advPD
and AP and define mechanism-based therapeutic approa-
ches that can be applied to different clinical entities, e.g.,
PD and MSA as synucleinopathies as currently investigated
for green tea component Epigallocatechin-gallate (EGCG)
that interferes with alpha-synuclein aggregation in vitro
and in vivo (Levin et al. 2016).
New treatment targets in advanced Parkinson’s
disease
Motor and non-motor symptoms acquire distinct charac-
teristics in advanced stages of PD that differ from early
stages (Olanow et al. 2009). It is important to note that not
only the symptom patterns become more complex with
progressing disease stages, but also more individualized.
Additionally, therapeutic options become more complex
for advPD, as there are surgical therapies, pumps, patches
or individualized combinations of different treatments
options. Thus, patient populations become more complex,
both for standardized assessments and clinical care. Tar-
geted therapies require substantial preselection of patients
based on their symptom patterns and outcome parameter
requires highly specialized questionnaires and examination
strategies. Pathomechanistic independency or confounding
between these symptoms, as well as their comparative
responsiveness to, e.g., dopaminergic treatment is only
partially understood. Also, preselection based on only a
limited number of symptoms can lead to highly conserved
patient cohorts within clinical trials that do not allow the
translation into other patient group with different symptom
patterns. Thus, an easy transfer from clinical studies with
the highest evidence level to patients at the same (ad-
vanced) disease stage within standard clinical management
becomes increasingly limited. Even though focused and
standardized clinical diagnostic queries and examination
protocols are able to assess the individual symptoms, their
contribution to the activities of daily living and patient
centered quality of life related outcomes is only partially
understood. Huge patient cohorts and objective targets are
required to understanding this complexity between indi-
vidual symptom patterns, highly focused assessment
strategies, pathomechanistic causal relationships, and
resulting consequences for the overall quality of life in
patient-centered clinical management and care concepts.
Within the emerging area of healthcare technology,
developments in PD objective assessment strategies
become increasingly developed and studied focusing on the
variety of motor and non-motor symptoms in PD (Klucken
et al. 2013; Maetzler et al. 2016). In contrast to novel
imaging strategies that become more sensitive to structural
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and functional neurodegenerative changes, wearable tech-
nologies become increasingly inexpensive and allow for
the objective assessment of distinct symptoms in PD (Es-
pay et al. 2016). Even though most of the new technologies
still lack the required technological readiness level (Sa´n-
chez-Ferro et al. 2016), they clearly pave the way for a
substantial change in diagnostic and treatment paradigms.
Two different concepts have to be distinguished on how
technology supports both clinical care and studies: while
several systems aim to improve the accuracy and compa-
rability of standardized clinical assessment tests already
used especially in clinical studies (e.g., improving tremor
rating of related items of the UPDRS), others aim to assess
new clinically relevant targets from the everyday life of the
patient reaching out to individualized continuous moni-
toring concepts. Ideally, a new technology would present a
sensor—or a group of sensors—that assesses all the rele-
vant symptoms of an individual patient continuously
resulting in an individualized pattern and objective score
exactly predicting the health-related quality of life. It is
evident that this predicted scenario is likely to be sub-
stantially more complex than the above-mentioned strati-
fication options in advanced PD. Nevertheless, these
increasingly easy-to-use assessment strategies allow han-
dling this complexity using modern big data mining
strategies and machine learning support.
A good example is the concept supported by mPower: a
relative simple smartphone-app assesses with short ques-
tions or easy motor tasks a complex pattern of features for
each patient. Since it is easy to download and install,
already over 9.500 patients have registered and include
their data (Bot et al. 2016). The implementation of novel
technologies ultimately has the potential to provide pat-
terns of symptoms extracted from real-life patient scenarios
and allows for a more direct and active participation of
patients to research programmes, which might improve
their quality of life (Van Uem et al. 2016). Today a great
number of different technologies for domestic monitoring
of motor symptoms do exist, ranging from wearable sen-
sors to non-wearable devices or gait labs (Godinho et al.
2016). Non-motor symptoms like sleep quality, skin
humidity or cardiovascular function can also be monitored,
but still need development to improve practicability and
consequently adherence of the patient to the device-based
assessment (Espay et al. 2016).
Nevertheless, a substantial amount of validation work is
required, in particular, because the patient inclusion criteria
are not limited or supervised by trained movement disorder
specialists. Also, it is not clear, which of these ‘‘new’’
target parameters is able to measure therapeutic effects in
each dimension. In addition, regulatory aspects for medical
technologies as well as data safety and privacy concerns
have to be developed and met. This also requires new IT-
based communication strategies that connect and harmo-
nize the team of multidisciplinary care, and modular
selection strategies for distinct technologies assessing the
symptom pattern of each individual patient. If these goals
are reached, it is possible to provide the best care concept
for patients within standardized clinical management and at
the same time provide stratified real-life targets for clinical
studies. The coming years have to prove the clinical
validity and applicability within this emerging field of
technology in PD (Pasluosta et al. 2015).
Stratification for therapeutic outcomes
Based on the increasingly recognized heterogeneity of
PD—not only in terms of underlying genetic and/or envi-
ronmental causes, but also in terms of clinical presenta-
tions—there is an emerging need for better definitions of
subtypes of PD that allow to assign treatments and shape
therapeutic approaches according to the best response. As
there is still no established neuroprotective treatment
option that is able to intervene with the chronic neurode-
generative process, most benefit for the patients in terms of
quality of life can be currently achieved by providing
access to best symptomatic treatment. This is also reflected
by the fact that clinical trials focus on more meaningful
parameters in terms of primary and secondary outcomes
(Mestre et al. 2015; Schuepbach et al. 2013). Complica-
tions of symptomatic pharmacological treatment of PD like
dyskinesia remain a significant problem and several recent
trials failed to efficiently target dyskinesia at phase III level
(Mestre et al. 2014; Orloff et al. 2009). Therefore, the
translation of novel drugs into successful trials requires the
definition of ‘clinically important change’ that goes beyond
the application of clinical rating scales and aligns with the
patient’s observation, e.g., of remission and perception of
dyskinesia.
Similarly, quality of life is a relevant clinical outcome
parameter and in studies investigating the role of deep brain
stimulation (DBS) in advPD (Deuschl et al. 2006). The
results of the EARLYSTIM study supported this concept
and indicated that DBS was superior to best pharmacologi-
cal treatment in younger PD patients with early motor
fluctuations (Schuepbach et al. 2013). Therefore, age or
disease stage of patients may represent first clinical strati-
fiers for more adapted symptomatic treatment approaches.
However, these criteria only apply at the group level and
more advanced strategies to predict therapeutic outcomes
that include additional, objective traits for personalized
treatment recommendations are highly warranted.
Here, genetic stratification has already proven effective
in the treatment of different forms of cancer, either by
defining tumor subtypes more or less responsive to
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therapies (e.g., in ovarian cancer by genotyping BRCA1/2
variants) or by defining a profile of the individual metab-
olizing capacities in terms of pharmacogenomics (Relling
and Evans 2015). Recently, first pilot studies were pub-
lished for PD patients and correlated positive treatment
outcomes for symptomatic pharmacological or interven-
tional therapies with specific genotypes in candidate genes.
In a first study, DNA samples from 692 participants of
the ADAGIO study that represented the largest clinical trial
of early stage PD patients under monotherapy with rasag-
iline were genetically stratified for 197 genetic polymor-
phisms from 20 candidate genes (Masellis et al. 2016). The
candidate genes were chosen by their involvement in
rasagiline’s mode of action or metabolism or based on
previously reported genetic association with PD in gen-
ome-wide association studies (GWAS). The authors found
a polymorphism in the dopamine D2 receptor gene as
predictive for a meaningful clinical response to rasagiline
treatment (Masellis et al. 2016). This effect was not asso-
ciated with the rate of symptom progression during the trial
period. As the beneficial genotype of the DRD2 receptor
gene was associated with structural changes leading to a
‘short isoform’ of the DRD2 receptor, the authors specu-
lated that increased dopamine levels due to monoamine
oxidase B inhibition by rasagiline would lead to a greater
increase in cortico–striato–thalamo–cortical motor activity
resulting in improvement in PD symptoms.
Another study investigated the contribution of genes to
the positive therapeutic outcome in PD patients treated
with DBS. Therefore, polymorphisms in the alpha-synu-
clein gene and LRRK2 gene were investigated in a cohort
of 85 PD patients treated with DBS in the subthalamic
nucleus (STN) and followed for more than 2 years after
implantation. The candidate genes were chosen based on
the fact that both consistently found associated with PD in
large GWAS studies from different populations worldwide
(Simon-Sanchez et al. 2009; Nalls et al. 2014). Interest-
ingly, a certain allele of the alpha-synuclein polymorphism
predicted a positive outcome of DBS in a dose-dependent
manner with homozygous carriers showing the most pro-
nounced benefit (Weiss et al. 2016). The same genetic
variant was linked to reduced expression of the PD-asso-
ciated alpha-synuclein protein in different brain areas
assessed by different post-mortem studies (Linnertz et al.
2009; Fuchs et al. 2008). This may indicate that the burden
of alpha-synuclein accumulation could relate to the integ-
rity of the basal ganglia loops that are critical for effective
neuromodulation. In support of this hypothesis, the same
alpha-synuclein polymorphism that was associated with
reduced expression of alpha-synuclein in human brains was
associated with PD without cognitive impairment in a
recent association study on PD patients with and without
dementia (Guella et al. 2016). This further supports the
concept of genetic variants in the alpha-synuclein gene as
potential tools for stratification in clinical trials.
The previous findings on pharmacological or neuro-
modulation therapy still require validation in independent
cohorts, which are difficult to find due to the clinically
well-characterized cohorts that served as starting points for
the pilot studies and, therefore, should stimulate efforts for
deep phenotyped patient cohorts for translational research.
These cohorts will be also critical for the development of
clinical trials that focus more on individual not average
therapeutic response.
Current medications provide efficacy only in a subset of
patients, e.g., only 1 in 50 patients benefit from statins used
to lower cholesterol (Mukherjee and Topol 2002). The
underlying clinical trials collected a handful of parameters
from a large number of study participants. Future trials for
more precise medical treatment approaches will be
designed to capture a large number of different parameters,
but only in limited number of participants to allow for
assessing the individual patient’s response to therapy. The
growing interest in ‘omics’ assays that define the individual
characteristics on the molecular level and also include
genetic profiles and metabolomics will help to avoid side
effects and predict more precisely drug–drug interactions.
The latter are frequently observed in PD as advanced stages
in patients with typically advanced age currently imply
polypharmaceutical approaches.
Practical aspects for the implementation
of advanced treatments
In the past few years, the treatment of PD has become
increasingly complex and it is expected to be more
individualized in the future, which implies novel strate-
gies for best practices to define and convey best treatment
options to patients with advPD. Current guidelines are a
helpful tool in the diagnostics and therapeutic decision
making in the early stages of disease; however, there is
not enough reliable information on how to implicate the
suggested strategies in the everyday neurological practice.
In addition, there is little specific information on possi-
bilities of influencing the course of disease progress. In
addition to the usage of the oral medication in the early
stages of the disease, there has been an increase in
application of the interventional therapies such as deep
brain stimulation and pump therapies. These highly
specific treatment options are mostly implemented in
specialized clinics or practices for movement disorders.
Here, the optimal timing for initiating advanced therapies
to improve the quality of life and prevent complications is
critical and requires an early information of patients and
caregivers about the later stages of the disease with its
complications.
R. Kru¨ger et al.
123
To avoid and/or to reduce anxiety and rejection, suffi-
cient and regular explanation about the possible therapies
at early stages of disease can widen opportunities for
overall therapeutic strategies. The practicing neurologists
should be involved in rounds for movement disorders as
part of the extended therapeutic concept (Kru¨ger et al.
2015). Pharmacists and medical associations also serve as
an important source of information for patients, less so the
peer groups and the health insurances. It is not clear to
what extent this applies to PD patients. Since the thera-
peutic decisions for PD patients are seldom based on sci-
entific studies, it is important to provide information to all
the involved persons.
To adapt information on therapies to the specific
requirements of the patient is important and will reassure
engagement of the patient. The passing on of information is
critical and has to be addressed appropriately, in order to
achieve adequate adherence to therapy and to deal effi-
ciently with possible complications. Here, different types
of patients may require specific approaches. The young
informed patient is often shocked at delivery of diagnosis
and, therefore, needs extended information. Management
of these patients is usually not problematic; however, the
digital information overflow can pose obstacles and lead to
anxieties. Therefore, it is essential to offer low-threshold
and frequent explanatory briefings. This is the basic prin-
ciple in the therapy of PD: the extensive information about
the disease itself (motor/non-motor symptoms), the course
of disease and its therapy has to be often repeated and
explained. As in many chronic diseases, suppression tends
to be a common psychological strategy in coming to terms
with the disease. Partner of the patient is often the one to
communicate with the physician. It is of great importance
to involve the patient in the conversation. In later stages of
disease, symptoms can be misinterpreted and increase of
side effects and complications can occur due to self-regu-
lation of the dosage of medication. The patient manage-
ment in such cases can be time consuming. Here,
specialized Parkinson nurses are available to answer dis-
ease-related or care-related questions and to manage
administrative issues.
Recent technological developments allow for the inte-
gration of interactive information platforms in patient
information and feedback. Appropriate feedback mecha-
nisms and evaluation system in corresponding online por-
tals have to be available. Implementing interactive
platforms in the practice setting would provide more
transparency and simplify feedback and evaluation for
more efficient patient empowerment and allow for the
implementation of interactive communication in the
ambulatory patient care in the near future (Chiauzzi et al.
2016).
Outlook
As PD is increasingly recognized as a heterogeneous dis-
order, and especially the advanced stages of the disease
with complex interplay of motor and non-motor symptoms
demand for more individual adaptation, careful drug titra-
tion and combination of therapies. As advPD patients are
typically older and subject to multiple co-morbidities,
classical drug targeting strategies derived from large clin-
ical trials in unselected patients do not translate directly
into clinical practice. It is, therefore, not surprising that
within this framework the concept of disease modification
has more or less failed from the clinicians’ point of view.
Therefore, novel approaches that take into account the
heterogeneity of advPD and translate into novel clinical
study concepts are required.
To date, etiology of sporadic PD is still unknown. As an
example, it is far from clear whether increased nigral and
striatal Lewy Body (LB) occurrence is a specific process
responsible for onset of PD or whether it is the result of a
secondary pathological process. Actually, the term PD
describes a concept for an entity of different subtypes.
There is a certain overlap between each of them and not all
share the same neuropathologically driven concept of
increased LB presence as essential feature of PD (Braak
et al. 2003; Beach et al. 2009). In this regard, current
research on genetics helped to define rare forms of
monogenic PD and rare genetic variants with significant
effects like mutations in the glucocerebrosidase (GBA)
gene; however, genome-wide association studies (GWAS)
do not yet allow to classify all the different, still not well-
characterized clinical subtypes of sporadic PD. Moreover,
the contribution of environmental influences, chronic
exposure to toxins, such as pesticides, to cause PD syn-
dromes in predisposed individuals is still unknown. This
specifically concerns advPD patients, as the progression
that defines the point, when patients reach this so-called
advanced stage of the disease is based on individual dif-
ferences in disease expression, e.g., with GBA-related PD
presenting with more prominent cognitive impairments and
axial symptoms related to advPD (Brockmann et al. 2015).
During neurodegeneration in PD, various neuronal death
mechanisms occur. Nearly, all of them end up in a cell death
cascade of increased oxidative stress, glutamate toxicity the
final step of apoptosis. Clinical research on regenerative
therapies needs to account for the variety of the PD subtypes
and the further probable impact of epigenetic, environmen-
tal, toxicological and infectious stressors on onset and pro-
gression of PD. Yet, neuroregenerative approaches were
only successful in experimental research based on a single
pathological process, e.g., by toxin rodent models, e.g., with
6-OH-dopamine, rotenone or 1-methyl-4-phenyl-1,2,3,6-
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tetrahydropyridine (MPTP) application that rarely model the
chronic neuronal cell death particularly in non-dopaminergic
systems, and sometimes overestimated the ability of in vitro
and in vivo PD models to translate into therapies that delay
or prevent advPD stages.
Thus, therapeutic stimulation of endogenous repair
mechanisms for affected glial and neuronal cells is urgently
needed and not only dopamine substitution in the nigros-
triatal system. This approach would well be accepted by
patients (even in earlier stages), caregivers and physicians,
because it may prevent or reverse the advPD. One candi-
date for such a more general approach is the modulation of
the repulsive guidance molecule A (RGMa). This protein is
involved in the physiologic repair mechanisms of neurons.
Therapeutic RGMa decrease supports regeneration of
lesioned neurons according to experimental findings in
various acute and chronic experimental models of nervous
system diseases independent of inflammatory, degenerative
or ischemic origin (Tao et al. 2013; Demicheva et al.
2015).
Generally, efficacious treatment of advPD implies an
intervention-specific risk (e.g., surgical procedure for DBS)
and may cause at least temporary adverse effects. Thus,
clinicians together with their more and more well-informed
patients, respectively caregivers, discuss an individual
therapeutic risk benefit ratio. This is the essential precon-
dition to initiate and to perform more personalized
therapies.
Currently, clinicians use a certain drug portfolio for
amelioration of PD symptoms by establishing an individ-
ually balanced and combined drug cocktail. Careful and
slow titration with continuous consideration of the tolera-
bility, safety and the needs of the patients and their care-
givers is the precondition for a successful treatment of PD
in the long term and especially in advPD. However, stan-
dardized treatment approaches with guidelines derived
from classical clinical trials with highly selected patients
may be limited, when heterogeneous subtypes of advPD
are treated in clinical practice (Weiner et al. 2009). Clini-
cians acknowledge that each PD patient is different; how-
ever, it requires novel clinical trial designs and further
operationalization of stratification criteria to translate this
concept into guidelines. This requires more individualized
trials as part of the mix and value the observation in single
patients.
Already in the past relevant advances in the drug
treatment of PD patients were contributed by clinicians and
their patients via close observations of clinical symptoms
and therapeutic effects. Typical examples are the intro-
duction of levodopa therapy by Birkmayer and Hornykie-
wicz (1961) or the clinical discovery on the efficacy of
amantadine on motor behavior in one PD patient during the
treatment of influenza (Schwab et al. 1969). The latter case
indicates that observations in single individuals can be still
meaningful, e.g., in terms of hypothesis generation, and
may be subsequently translated into larger trials. In contrast
to former single case reports, the technological advances
permit today to perform multiple simultaneous measure-
ments of different biological parameters within one indi-
vidual at reasonable costs. This is in line with recent
initiatives from life sciences funding bodies and govern-
ments that increasingly support more targeted treatment
approaches and patient empowerment.
Therefore, based on new options for deep phenotyping
advPD patients using (1) molecular strategies (‘omics’-
based assessment of metabolome, genome, transcriptome,
proteome), (2) mobile devices for more objective health
data (e.g., accelerometers, smartphone apps) and (3)
engagement of patients in medical research, novel designs
for clinical trials emerge (Fig. 1). This allows for tailoring
dosages to individual metabolic profiles and avoid testing
of medication in a large number of unselected patients,
typically including a substantial number of non-respon-
ders to establish precision medicine (Schork 2015). The
underlying, so-called one-person trials focus on
Fig. 1 Precision medicine—novel designs for clinical trials. advPD
advanced Parkinson’s disease, AP atypical parkinsonism, HY
Hoehn&Yahr
R. Kru¨ger et al.
123
individual, not average, therapeutic response and, there-
fore, account for the whole complexity of different sub-
types of advPD. Given such visions, we should be able to
implement with much easier protocols, i.e., avoiding
drug–drug interactions by introducing individualized drug
monitoring especially (but not exclusively) in advPD.
These patients are typically not reflected in standard
clinical trials and treated with a variety of drugs, e.g., for
mental, autonomic and sensory dysfunction, and thus
combine multiple drugs with very different pharmaco-
logical mechanisms, which may interfere and cause
(severe) adverse drug reactions (Hiemke et al. 2011).
Thus, future trials will prove the effectiveness of a novel
therapy within individual patients and, therefore, treat-
ment benefit will be delineated in the actual participant
and account for possible interactions avoiding side
effects.
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